ALCAMI CAROLINAS CORPORATION

ALCAMI CAROLINAS CORPORATION specializes in pharmaceutical and biopharmaceutical manufacturing services, with core expertise in active pharmaceutical ingredient (API) development, aseptic processing, and sterile product formulation. The company provides end-to-end contract development and manufacturing organization (CDMO) capabilities, including process scale-up, analytical method validation, and regulatory support aligned with cGMP standards. Their technical proficiency spans lyophilization, fill-finish operations, and drug substance stability testing, with a focus on meeting FDA and EMA compliance requirements. A key differentiator is their precision in handling complex modalities such as injectables and high-potency compounds, supported by validated cleanroom environments and rigorous quality control protocols. No agency relationships can be inferred from available award data, as no recent contracts or agency-specific performance records are documented. Consequently, there is no observable pattern of engagement with federal, state, or defense entities. The primary NAICS code 325412 corresponds to pharmaceutical preparation manufacturing, indicating the contractor’s operational focus on the production of finished dosage forms and intermediate pharmaceutical products. This positions ALCAMI CAROLINAS CORPORATION within the biopharmaceutical supply chain, serving clients requiring compliant, small-to-medium batch manufacturing for clinical and commercial use. Their market positioning emphasizes niche expertise in sterile and specialty drug manufacturing rather than broad-scale commodity production. The entity operates as a 2L structure based in Wilmington, North Carolina, with no publicly disclosed government certifications such as 8(a), HUBZone, or WOSB. The facility serves as a dedicated manufacturing site with no indication of multi-location operations. While the company maintains a focused geographic footprint, its capabilities are aligned with the demands of regulated life sciences markets, positioning it as a specialized partner for biotech and pharmaceutical firms requiring validated, compliant production infrastructure.